Articles

Burden of cancer attributable to high body mass index: A systematic analysis of the Global Burden of Disease Study 2021

Gisella Figlioli , Daniele Piovani , Andreas G Tsantes et al. Clinical Nutrition 48 (2025) 144e152

High body mass index (BMI) is a well-established cancer risk factor. Reliable, updated data are essential for guiding public health policies and designing effective interventions to reduce the cancer burden associated with high BMI. In 2021, cancer attributable to high BMI resulted in 356.74 thousand deaths and 8.89 mi... Read More

24 Mar, 2026

The Lancet Commission on prostate cancer: planning for the surge in cases

Nicholas D James, Ian Tannock, James N'Dow, et al. Lancet. 2024 Apr 27;403(10437):1683-1722

Prostate cancer is the most common cancer in men in 112 countries, and accounts for 15% of cancers. In this Commission, we report projections of prostate cancer cases in 2040 based on data for demographic changes worldwide and rising life expectancy. Our findings suggest that the number of new cases annually will rise ... Read More

24 Mar, 2026

Recent Patterns and Trends in Global Prostate Cancer Incidence and Mortality: An Update

Elizabeth J Schafer, Mathieu Laversanne , Hyuna Sung , et al. Eur Urol. 2025 Mar;87(3):302-313

Our aim was to examine worldwide patterns and trends for prostate cancer (PC) incidence and mortality using high-quality, up-to-date, population-based data.  Estimated PC rates across regions in 2022 varied 13-fold for incidence and 9.5-fold for mortality. The highest incidence rates were in Australia/New Zealand, Nort... Read More

24 Mar, 2026

Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy

Julio Garcia-Aguilar 1, Sujata Patil 2, Marc J Gollub 3, et al. J Clin Oncol. 2022 Aug 10;40(23):2546-2556

In this prospective, randomized phase II trial, we assessed the outcomes of 324 patients with stage II or III rectal adenocarcinoma treated with induction chemotherapy followed by chemoradiotherapy (INCT-CRT) or chemoradiotherapy followed by consolidation chemotherapy (CRT-CNCT) and either total mesorectal excision (TM... Read More

24 Mar, 2026

The triple effect of colorectal cancer screening: reducing deaths, government spending, and mortality disparities

Pedro Nascimento de Lima , Lillian Bartholomew , Folasade P May, et al. J Natl Cancer Inst. 2026 Feb 1;118(2):360-363

Colorectal cancer (CRC) screening accounts for over 60% of cancer screening costs in the United States, prompting recurrent debates about its value. Yet CRC screening remains the main tool to curb overall CRC incidence, mortality, and disparities that affect Black Americans. Using the race-specific CRC-SPIN microsimula... Read More

24 Mar, 2026

Comparing cohort and period trends of early-onset colorectal cancer: a global analysis

Jianjiu Chen, and Wan Yang. JNCI Cancer Spectrum, 2024, 8(4), pkae052

 Incidence of early-onset colorectal cancer (CRC) has increased globally in recent decades. We examined early-onset CRC incidence trends worldwide for potential cohort effects, defined as changes associated with time of birth (eg, early-life exposure to carcinogens), and period effects, defined as changes associated wi... Read More

24 Mar, 2026

Colorectal Cancer: Epidemiology, Risk Factors, and Public Health Strategies

Takahisa Matsuda, Ai Fujimoto, Yoshinori Igarashi . Digestion. 2025;106(2):91-99

Colorectal cancer (CRC) is a significant global health issue, ranking as the third most commonly diagnosed cancer and the second leading cause of cancer-related deaths. Countries with a high Human Development Index (HDI) report the highest incidence rates, driven by dietary and lifestyle factors. In contrast, low-to-mi... Read More

24 Mar, 2026

European cancer mortality predictions for the year 2024 with focus on colorectal cancer

C. Santucci, S. Mignozzi, M. Malvezzi, et al. Ann Oncol. 2024 Mar;35(3):308-316

We predicted cancer mortality figures for 2024 for the European Union (EU), its five most populous countries, and the UK. We predicted cancer mortality figures for 2024 for the European Union (EU), its five most populous countries, and the UK. We predicted 1 270 800 cancer deaths for 2024 in the EU, corresponding to AS... Read More

24 Mar, 2026

Evolving landscape of colorectal cancer: Global and regional burden, risk factor dynamics, and future scenarios (the Global Burden of Disease 1990-2050)

Jiajie Zhou, Qizhi Yang, Shuai Zhao,et al. Ageing Res Rev. 2025 Feb:104:102666

Presently, colorectal cancer (CRC) is the second leading cause of cancer-related deaths worldwide. We provided global, regional, and national estimates of the burden of CRC and their attributable risks from 1990 to 2021, aiming to guide screening, early detection, and treatment strategies, optimize healthcare resource ... Read More

24 Mar, 2026

Global landscape of cervical cancer incidence and mortality in 2022 and predictions to 2030: The urgent need to address inequalities in cervical cancer

Zhuang Li, Penglin Liu, Aijun Yin,et al. Int. J. Cancer. 2025;157:288–297

Cervical cancer remains a major public health challenge worldwide, despite being largely preventable through effective interventions. Timely evidence regarding the global landscape of cervical cancer is crucial for measuring the magnitude of inequalities and monitoring progress towards cervical cancer elimination. We a... Read More

24 Mar, 2026